期刊文献+

神经重症科机械通气患者鲍曼不动杆菌感染耐药分析 被引量:2

Analysis of drug resistance of Acinetobacter baumannii infection in patients received mechanical ventilation in neurological ICU
下载PDF
导出
摘要 目的了解神经重症ICU患者机械通气下呼吸道鲍曼不动杆菌感染及耐药情况。方法对本院神经重症医学科住院机械通气患者鲍曼不动杆菌对临床常见抗生素耐药情况进行分析,并对治疗效果评价。结果 98例鲍曼不动杆菌对临床常见药物耐药非常严重,大部分均在60.00%以上,对多粘菌素敏感性最高,98例患者66例治愈或者好转,32例对治疗无效,其中死亡15例。结论本院神经重症医学科鲍曼不动杆菌耐药率非常高,多粘菌素可作为泛耐药鲍曼不动杆菌首选用药。 Objective To study the drug resistance of Acinetobacter baumannii infection in patients received mechanical ventilation in neurological ICU. Methods The drug resistance of Acinetobacter baumannii to common antibiotics was analyzed in 98 patients with mechanical ventilation in neurological ICU. Results The drug resistance of Acinetobacter baumannii to common antibiotics was serious,most of which was higher than 60. 00% and showed the highest sensitivity to polymyxin. There were 66 cases cured or improved,32 cases of ineffective treatment,including 15 cases died. Conclusion The drug resistance of Acinetobacter baumannii to common antibiotics is very high,and polymyxin can be used as the preferred drug.
出处 《临床肺科杂志》 2014年第8期1495-1496,共2页 Journal of Clinical Pulmonary Medicine
关键词 鲍曼不动杆菌 耐药性 机械通气 重症医学科 Acinetobacter baumannii resistance mechanical ventilation critical care medicine
  • 相关文献

参考文献9

二级参考文献76

共引文献697

同被引文献19

  • 1Ji J, Du X, Chen Y, et aL In vitro activity of sulbactam in combination with imipenem, me;ropenem,panipenem or cefoperazone against clinical isolates of Acinetobacter baumannii[J]. Int J Antimicrob Agents, 2013,41(4) :400-401.
  • 2Matthews P, Alpert M, Rahav G, et al. A randomized trial of tigecycline versus ampicillin-sulbactam or amoxicillin-clavu- lanate for the treatment of complicated skin and skin structure infections[J]. BMC Infect Dis, 2012,12 (17) : 297.
  • 3Deveci A, Coban AY, Acicbe O, et al. In vitro effects of sulbaetam combinations with different antibiotic groups a-gainst clinical Acinetobacter baumannii isolates[J]. J Che- mother,2012,24(5) :247-252.
  • 4Rodriguez-Hernandez MJ, Cuberos L, Pichardo C, et al. Sulbactam efficacy in experimental models caused by sus ceptible and intermediate Acinetobacter baumannii strains [J]. J Antimicrob Chemother, 2001,47 (4) : 479-482.
  • 5Kempf M, Djouhri-Bouktab L, BrUnel JM, et al. Synergis tic activity of sulbactam combined with eotistin against co- listin-resistant Acinetobacter baumannii[J]. Int J Antimi crob Agents, 2012,39 (2) : 180-181.
  • 6Cikman A,Ceylan MR, Parlak M, et al. Evaluation of Co listin-Ampicillin/Sulbactam Combination Efficacy in Imi penem-Resistant Acinetobacter baumann{i Strains [J]. Mikrobiyol Bul, 2013,47(1) : 147-151.
  • 7Kumar H,Salminen S,Verhagen H,et al.Novel probiot- ics and prebio tics:road to the market[J].Curr Opin Bio- technol,2015,32:99-103.
  • 8Matthews P,Alpert M,Rahav G,et al.A randomized trial of tigecycline versus ampicillin-sulbactam or amoxicillin- clavulanate for the treatment of complicated skin and skin structure infe,ctions[J].BMC Infect Dis,2012,12:297.
  • 9Abis GS,Oosterling SJ,Stockmann HB,et al.Periopera- tive selective decontamination of the digestive tract and standard antibiotic prophylaxis versus standard antibiotic prophylaxis alone in elective colorectal cancer patients[J].Dan Med J,2014,61(4):4695.
  • 10Duncan EM,Cuthbertson BH,Prior ME,et al.The views of health care professionals about 'selective decontamina don of the digestive tract:an international,theoretically informed interview study[J].J Crit Care,2014,29(4):634-640.

引证文献2

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部